CELLphenomics GmbH specializes in the development and cultivation of patient-derived 3D cell culture models, known as PD3D® models, which are derived from various solid tumor tissues. These models are designed to closely mimic the biological characteristics of the donor tumor, including key histopathological features and genomic profiles. The PD3D® platform is utilized for a range of applications, including high-throughput efficacy testing, drug combination screening, and toxicity profiling. This technology not only aids in understanding treatment sensitivity and resistance but also supports biomarker identification and target validation, making it a valuable tool for researchers in the field of oncology.

The company boasts a biobank that contains over 600 complex in vitro models representing major cancer types and rare tumors, complemented by clinical and molecular data. This extensive collection allows for a more comprehensive analysis of drug efficacy and safety, significantly reducing the time required for preclinical development compared to traditional models. CELLphenomics' PD3D® models are recognized for their predictive capabilities, which help de-risk clinical development and minimize the reliance on animal studies. Additionally, the company offers consulting services and advanced technologies, such as genomics and proteomics, to further enhance the drug development process for its clients.

Germany

CELLphenomics is a thriving and diverse place to work and learn. We offer fee-for-service research as well as research projects with academic partners on the local, national and EU level. Our partners, clients and staff, with representation from more than 20 countries, are brought together by the common goal of translational research.

CELLphenomics

Company Details